Search Result

Results for "

liver cirrhosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (3) Amyloid-β (1) Apical Sodium-Dependent Bile Acid Transporter (3) Apoptosis (1) Autophagy (1) Endogenous Metabolite (4) FOXO (1) FXR (1) HBV (1) HSV (1) Interleukin Related (2) Isotope-Labeled Compounds (2) Microtubule/Tubulin (1) NF-κB (1) PDGFR (1) Ser/Thr Protease (1) TGF-beta/Smad (1) TNF Receptor (1) VEGFR (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (7) Metabolic Disease (9) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0282

L-Ornithine L-aspartate	Others	Metabolic Disease Inflammation/Immunology
L-Ornithine L-aspartate is a stable salt of two natural nonessential L-amino acids with oral activity: ornithine and aspartic acid. L-Ornithine L-aspartate lowers blood ammonia concentration and to eliminate symptoms of hepatic encephalopathy associated with liver cirrhosis. L-Ornithine L-aspartate also improves mitochondrial functions .

HY-109120

Odevixibat 3 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-169004

CBT-295	TGF-beta/Smad Interleukin Related	Neurological Disease Inflammation/Immunology
CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy .

HY-148514

CT52923	PDGFR	Cancer
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer .

HY-157650

HSD17B13-IN-20	17β-HSD	Metabolic Disease
HSD17B13-IN-38 (Compound 18.02) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-157653

HSD17B13-IN-22	17β-HSD	Metabolic Disease
HSD17B13-IN-22 (Compound 18.03) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-22 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-157654

HSD17B13-IN-26	17β-HSD	Metabolic Disease
HSD17B13-IN-26 (Compound 18.04) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-26 can be used in the research of liver diseases such as hepatitis, liver fibrosis, liver cirrhosis, and hepatocellular carcinoma .

HY-109120S

Odevixibat-d5 A4250-d₅	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6 A4250-¹³C₆	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-126128

Heliotrine	Others	Cancer
Heliotrine is a monoester pyrrolizidine alkaloid and is used for obtaining models of hepatitis and cirrhosis of the liver .

HY-19421

Orazamide	Others	Inflammation/Immunology
Orazamide is an AICA orotate. Orazamide can prevent anti-TB drug-induced liver damage by downregulating the protein expression of HMGB 1 and RAGE in liver tissue and inhibiting the secretion of inflammatory factors. Orazamide can be used in research on hepatitis and liver cirrhosis .

HY-134221

S-Nitroso-N-acetylcysteine	Others	Cardiovascular Disease
S-Nitroso-N-acetylcysteine is a nitric oxide donor. S-Nitroso-N-acetylcysteine has a tissue vascular dilation effect, which can enhance liver microcirculation and effectively prevent ischemia-reperfusion injury in fatty liver. S-Nitroso-N-acetylcysteine can reduce liver fibrosis in rats with cirrhosis .

HY-109083A

Cilofexor tromethamine GS-9674 tromethamine	Autophagy FXR	Metabolic Disease
Cilofexor tromethamine (GS-9674 tromethamine) is a nonsteroidal farnesene oxide receptor agonist with activity in improving markers of cholestasis and liver injury. Cilofexor tromethamine was shown to be well tolerated in patients without cirrhosis and resulted in significant improvements in liver biochemical parameters and cholestatic markers. Cilofexor tromethamine offers a potential inhibitory option for the management of primary sclerosing cholangitis .

HY-P3465

Bulevirtide 1 Publications Verification Myrcludex B	HBV	Infection
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research .

HY-B1788

Taurocholic acid Maximum Cited Publications 11 Publications Verification Taurocholic Acid	Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N0545

Taurocholic acid sodium Maximum Cited Publications 11 Publications Verification Sodium taurocholate; N-Choloyltaurine sodium	VEGFR Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .

HY-B1788R

Taurocholic acid (Standard)	Endogenous Metabolite	Inflammation/Immunology
Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .

HY-N3021

D-chiro-Inositol	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin	Metabolic Disease
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N2127

Pinostrobin 1 Publications Verification	Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent PCSK9 inhibitor that inhibits the catalytic activity of PCSK9. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .

Cat. No.	Product Name

HY-L060

Cytoskeleton Compound Library	1,313 compounds
The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases. MCE designs a unique collection of 1,313 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

Cytoskeleton Compound Library

1,313 compounds

The cytoskeleton is responsible for contraction, cell motility, movement of organelles and vesicles through the cytoplasm, cytokinesis, intracellular signal transduction, and many other functions that are essential for cellular homeostasis and survival. It accomplishes these tasks through three basic structures: F-actin, microtubules, and intermediate filaments (IFs). The cytoskeleton is a dynamic structure where the three major filaments and tubules are under the influence of proteins that regulate their length, state of polymerization, and level of cross-linking. Since cytoskeleton is involved in virtually all cellular processes, cytoskeletal protein aberrations are the underlying reason for many pathological phenotypes, including several cardiovascular disease syndromes, neurodegeneration, cancer, liver cirrhosis, pulmonary fibrosis, and blistering skin diseases.

MCE designs a unique collection of 1,313 cytoskeleton-related compounds mainly focusing on the key targets in the cytoskeleton signal pathway and can be used in the research of cytoskeleton signal pathway and related diseases.

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library	3,225 compounds
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 3,225 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,225 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,225 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

HY-L101

Anti-Liver Cancer Compound Library	1,867 compounds
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers. Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc. MCE offers a unique collection of 1,867 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Anti-Liver Cancer Compound Library

1,867 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 1,867 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

HY-L073

Anti-Hepatitis C Virus Compound Library	295 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 295 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Anti-Hepatitis C Virus Compound Library

295 compounds

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 295 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Target	Research Area